SiJunZi decoction ameliorates bone quality and redox homeostasis and regulates advanced glycation end products/receptor for advanced glycation end products and WNT/β-catenin signaling pathways in diabetic mice

• Published in: Journal of ethnopharmacology 2024-01, Vol.319, p.117167-117167, Article 117167
• Main Authors: Dai, Xuan, Liu, Yage, Liu, Tianyuan, Zhang, Yueyi, Wang, Shan, Xu, Tianshu, Yin, Jiyuan, Shi, Hanfen, Ye, Zimengwei, Zhu, Ruyuan, Gao, Junfeng, Dong, Guangtong, Zhao, Dandan, Gao, Sihua, Wang, Xinxiang, Prentki, Marc, Brὂmme, Dieter, Wang, Lili, Zhang, Dongwei
• Format: Article
• Language: English
• Subjects: AGEs/RAGE/NF-κB; Bone remodeling; SiJunZi decoction; Type 2 diabetes; Wnt/β-catenin signaling
• ISSN: 0378-8741; 1872-7573
• DOI: 10.1016/j.jep.2023.117167

SiJunZi decoction (SJZD), one of the traditional Chinese medicine formulas, has been clinically and traditionally used to improve glucose and lipid metabolism and promote bone remodeling. To study the actions and mechanisms of SJZD on bone remodeling in a type 2 diabetes mouse model. Diabetic mice generated with a high-fat diet (HFD) and streptozotocin (STZ) were subjected to SJZD treatment for 8 weeks. Blood glucose and lipid profile, redox status and bone metabolism were determined by ELISA or biochemical assays. Bone quality was evaluated by micro-CT, three-point bending assay and Fourier transform infrared spectrum (FTIR). Bone histomorphometry alterations were evaluated by Hematoxylin-Eosin (H&E), tartrate resistant acid phosphatase (TRAP) staining and Safranin O-fast green staining. The expressions of superoxide dismutase 1 (SOD1), advanced glycation end products (AGEs), receptor for advanced glycosylation end products (RAGE), phosphorylated nuclear factor kappa-B (p–NF–κB), NF-κB, cathepsin K, semaphorin 3A (Sema3A), insulin-like growth factor 1 (IGF1), p-GSK-3β, (p)-β-catenin, Runt-related transcription factor 2 (Runx2) and Cyclin D1 in the femurs and/or tibias were examined by Western blot or immunohistochemical staining. The main constituents in the SJZD aqueous extract were characterized by a HPLC/MS. SJZD intervention improved glucose and lipid metabolism and preserved bone quality in the diabetic mice, in particular glucose tolerance, lipid profile, bone microarchitecture, strength and material composition. SJZD administration to diabetic mice preserved redox homeostasis in serum and bone marrow, and prevented an increase in AGEs, RAGE, p–NF–κB/NF-κB, cathepsin K, p-GSK-3β, p-β-catenin expressions and a decrease in Sema3A, IGF1, β-catenin, Runx2 and Cyclin D1 expressions in tibias and/or femurs. Thirteen compounds were identified in SJZD aqueous extract, including astilbin, liquiritin apioside, ononin, ginsenoside Re, Rg1, Rb1, Rb2, Ro, Rb3, Rd, notoginsenoside R2, glycyrrhizic acid, and licoricesaponin B2. SJZD ameliorates bone quality in diabetic mice possibly via maintaining redox homeostasis. The mechanism governing these alterations are possibly related to effects on the AGEs/RAGE and Wnt/β-catenin signaling pathways. SJZD may offer a novel source of drug candidates for the prevention and treatment of type 2 diabetes and osteoporosis. [Display omitted] •HFD and STZ induces a disorder in bone and glucolipid metabolism in mice.•SJZD amelior